Interaction between substituted 1-[2-(diphenylmethoxy)ethyl] piperazines and dopamine receptors

doi:10.1016/0028-3908(85)90150-9

Paper

DOI: 10.1016/0028-3908(85)90150-9

Interaction between substituted 1-[2-(diphenylmethoxy)ethyl] piperazines and dopamine receptors

Published Dec 1, 1985 · P. Zee, W. Hespe

Neuropharmacology

Q1 SJR score

Citations

Influential Citations

Full textSemantic Scholar

Abstract

Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.

In Vitro Study

Study Snapshot

Substituted 1-[2-(diphenylmethoxy)ethyl]piperazines can effectively displace dopamine from binding sites in the rat corpus striatum, with IC 50-values in the order of 10 nM.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Sign up to use Study Snapshot

Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.

Create an account

Full text analysis coming soon...

References

DOI: 10.1016/0014-2999(84)90483-7

Behavioral properties of GBR 12909, GBR 13069 and GBR 13098: specific inhibitors of dopamine uptake.

GBR 12909, GBR 13069, and GBR 13098 are potent inhibitors of dopamine uptake in vitro and exhibit dopaminergic activity in vivo, making them potential pharmacological agents.

1984·232citations·R. Heikkila et al.·European journal of pharmacology

European journal of pharmacology

DOI: 10.1016/0006-2952(84)90436-2

Criteria for receptor sites in binding studies.

Applying strict criteria is crucial for interpreting binding study results, avoiding fanciful interpretations and potential pitfalls.

1984·129citations·P. Laduron·Biochemical pharmacology

Biochemical pharmacology

DOI: 10.1111/j.2042-7158.1980.tb12987.x

2‐Amino‐6,7‐dihydroxytetrahydronaphthalene and the receptor‐site preferred conformation of dopamine—a commentary

2-Amino-6,7-dihydroxytetrahydronaphthalene may play a role in understanding dopamine's receptor-site preferred conformation.

1980·20citations·A. Horn et al.·Journal of Pharmacy and Pharmacology

Journal of Pharmacy and Pharmacology

DOI: 10.1016/0014-2999(78)90019-5

Inhibition of synaptosomal uptake of norepinephrine and dopamine by conformationally restricted sympathomimetic amines.

The anti conformation of sympathomimetic amines is the preferred conformation at the noradrenergic amine pump, mainly inhibiting synaptosomal accumulation of norepinephrine and dopamine.

1978·4citations·H. Komiskey et al.·European journal of pharmacology

European journal of pharmacology

DOI:

Steric aspects of dopaminergic drugs.

The trans extended form of dopamine is the optimal form for binding to dopamine receptors, with high stereospecificity observed in various dopaminergic systems.

1978·5citations·Miller Dd

DOI: 10.1021/JM00206A023

Facile syntheses of potent dopaminergic argonists and their effect on neurotransmitter release.

Facile syntheses of potent dopaminergic argonists, 11, 12, and their effects on neurotransmitter release show the importance of catechol function in this uptake-release process.

1978·44citations·A. Horn et al.·Journal of medicinal chemistry

Journal of medicinal chemistry

DOI: 10.1073/PNAS.75.6.2641

Conformation of dopamine at the dopamine receptor.

Dopamine preferentially interacts with the dopamine receptor in the trans conformation, with two binding sites in rat and calf membranes.

1978·21citations·H. Komiskey et al.·Proceedings of the National Academy of Sciences of the United States of America

Proceedings of the National Academy of Sciences of the United States of America

DOI: 10.1111/j.1476-5381.1978.tb07788.x

THE UPTAKE AND RELEASE OF [3H]‐2‐AMINO‐6,7‐DIHYDROXY1,2,3,4‐TETRAHYDRONAPHTHALENE (ADTN) BY STRIATAL NERVE TERMINALS

ADTN is accumulated preferentially in areas of the rat brain rich in dopamine, and may act as a false transmitter when released by elevated K+ and calcium ionophore.

1978·12citations·A. Davis et al.·British Journal of Pharmacology

British Journal of Pharmacology

DOI: 10.1016/0006-2952(78)90159-4

Inhibition of [3H]dopamine accumulation in rat striatal synaptosomes by psychotropic drugs.

Psychotropic drugs can inhibit dopamine accumulation in rat striatal synaptosomes, but this test is not predictive of their clinical effects in humans.

1978·72citations·J. Hyttel·Biochemical pharmacology

Biochemical pharmacology

Citations

DOI: 10.1016/j.neuro.2008.06.003

Different effects of selective dopamine uptake inhibitors, GBR 12909 and WIN 35428, on HIV-1 Tat toxicity in rat fetal midbrain neurons.

GBR 12909, a selective dopamine transporter inhibitor, mimics cocaine-induced neurotoxicity in rat fetal midbrain cells, while WIN 35428 does not.

2008·26citations·M. Aksenov et al.·Neurotoxicology

Neurotoxicology

DOI: 10.1021/JM0490235

Synthesis and pharmacology of 6-substituted benztropines: discovery of novel dopamine uptake inhibitors possessing low binding affinity to the dopamine transporter.

6-substituted benztropines show significant dopamine uptake inhibitory activity with low binding affinity to the dopamine transporter, making them potential new drugs for treating Parkinson's disease.

2005·6citations·D. Simoni et al.·Journal of medicinal chemistry

Journal of medicinal chemistry

DOI: 10.1016/S0969-8051(02)00420-1

Synthesis and in vivo evaluation of novel radiotracers for the in vivo imaging of the norepinephrine transporter.

(S,S)-[11 C]-MeNER shows potential as the first successful PET ligand to image the norepinephrine transporter in vivo.

2003·93citations·Alan A. Wilson et al.·Nuclear medicine and biology

Nuclear medicine and biology

DOI: 10.1021/AC00205A011

In vivo microdialysis and thermospray tandem mass spectrometry of the dopamine uptake blocker 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)-piper azine (GBR-12909).

GBR-12909 has a 40-fold lower concentration in the brain compared to cocaine at 30 mg/kg, potentially explaining the discrepancy between in vivo and in vitro potencies of the two drugs.

1990·32citations·S. Menacherry et al.·Analytical chemistry

Analytical chemistry

DOI: 10.1002/JLCR.2580271109

A one‐pot radiosynthesis of [125I]iodoazido photoaffinity labels

This one-pot radiosynthesis method provides high specific activity radioiodinated photoaffinity labels with 40-64% radiochemical yields, minimizing radioactive material handling and chromatography purification.

1989·17citations·Alan A. Wilson et al.·Journal of Labelled Compounds and Radiopharmaceuticals

Journal of Labelled Compounds and Radiopharmaceuticals

DOI: 10.1007/BF00169305

Further in vitro and in vivo studies with the putative presynaptic dopamine agonist N,N-dipropyl-7-hydroxy-2-aminotetralin

The dopamine autoreceptor agonist [3H]DP-7-ATN shows no direct binding to DA autoreceptors, suggesting that release-regulating and biosynthesis-regulating autoreceptors may be different entities.

1987·5citations·T. B. Mulder et al.·Naunyn-Schmiedeberg's Archives of Pharmacology

Naunyn-Schmiedeberg's Archives of Pharmacology

DOI: 10.1007/978-1-59259-158-9_11

Dopamine-Transporter Uptake Blockers

Dopamine-transporter uptake blockers may be effective in reducing cocaine's drug reinforcement by inhibiting its binding to the DAT site in the brain.

1997·17citations·F. Carroll et al.

DOI: 10.1016/0024-3205(88)90431-6

Further analysis of the neuropharmacological profile of 9-amino-1,2,3,4-tetrahydroacridine (THA), an alleged drug for the treatment of Alzheimer's disease.

THA, an alleged Alzheimer's disease treatment, may contribute to its therapeutic action by inhibiting monoaminergic neurotransmission.

1988·82citations·B. Drukarch et al.·Life sciences

Life sciences